SCHEMBL6824626

SCHEMBL6824626

COc1ccn2nc(-c3ccccc3F)c(-c3ccc(=O)n(C(C)C)n3)c2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
GSK3B P49841 1/20 0.33
QPCT Q16769 1/20 0.33
MAT2A P31153 1/20 0.33
DHODH Q02127 1/20 0.33
FGFR1 P11362 1/20 0.33
FGFR2 P21802 1/20 0.33
FGFR3 P22607 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
MAPT P10636 4/20 0.32
GAA P10253 3/20 0.32
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
PDE2A O00408 1/20 0.32
PDE10A Q9Y233 1/20 0.32
IDO1 P14902 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6824871 0.87 NPC1 (0.38) NPC1RAB9AGSK3BQPCTPTGDR2
SCHEMBL6821959 0.86 ADORA1 (0.42) FGFR1FGFR2FGFR3PTGDR2
SCHEMBL6818465 0.84 MAPK14 (0.42) GSK3BFGFR1FGFR2FGFR3MAPT
SCHEMBL7367567 0.81 MAT2A (0.33) MAT2A
SCHEMBL6821911 0.80 PDE3A (0.44) NPC1RAB9AGSK3BQPCTDHODH
SCHEMBL6822033 0.77 ADORA1 (0.41)
SCHEMBL6822257 0.77 ADORA1 (0.43) SMN1; SMN2
SCHEMBL8193926 0.77 ADORA1 (0.45) DHODHPDE5APDE3AMAOB
SCHEMBL6822483 0.77 CMKLR1 (0.42) RAB9ASMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL6822329 0.76 ADORA1 (0.41) PTGDR2MAPTSMN1; SMN2PDE5APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 NPC1 1281/4885RAB9A 1138/4885GSK3B 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.